EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist

Jarosz-Biej Magdalena, Czapla Justyna, Ciepła Joanna, Smolarczyk Ryszard, Drzyzga Alina, Sprus-Lipka Dorota, Pilny Ewelina, Matuszczak Sybilla, Cichoń Tomasz

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-03943-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Jarosz-Biej Magdalena und 8 weiteren Autor:innen. Beteiligte Einrichtung: Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Po…. Hauptthemen laut MEDLINE: Imiquimod, Toll-Like Receptor 7, Neovascularization, Pathologic, Antineoplastic Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Science Centre, Poland.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Imiquimod (IMQ), a drug from aminoquinoline group, is the toll-like receptor 7 (TLR7) agonist. It acts as an immunostimulant and radio-sensitizing agent. IMQ stimulates both innate and adaptive immune response. Despite studies conducted, there are no unambiguous data showing how IMQ affects the condition of tumor blood vessels. Tumor vasculature plays the main role in tumor progression. Formation of abnormal blood vessels increases area of hypoxia which recruits suppressor cells, blocks tumor infiltration by CD8 + T lymphocytes, inhibits efficacy of chemoterapeutic drug and leads to cancer relapse. Normalization is a type of therapy targeted at abnormal tumor blood vessels. Here, we demonstrated that 50 µg of IMQ inhibits the growth of melanoma tumors more efficiently, compared to other tested doses and the control group. Dose escalation did not improve the therapeutic antitumor potential of TLR7 agonist. A dose of 50 µg of IMQ most effectively reduced tumor blood vessel density. Imiquimod normalized tumor vasculature both structurally (by reducing vessel tortuosity and increasing pericyte coverage) and functionally (by improving tumor perfusion) in a dose-dependent manner. Hypoxia regions in tumors of treated mice were significantly reduced after IMQ administration. A dose of 50 µg of IMQ had also the greatest impact on the changes in tumor-infiltrating T lymphocytes levels. TLR7 agonist inhibited angiogenesis in treated mice. Functional vascular normalization by IMQ increases the effectiveness of low dose of doxorubicin. Higher dose of IMQ showed worse effects than lower doses including decreased tumor perfusion, increased tumor hypoxia and immunosuppression. This knowledge may help to optimize the combination of the selected IMQ dose with e.g. chemotherapy or radiotherapy to elicit synergistic effect in cancer treatment. To conclude, we outline IMQ repurposing as a vascular normalizing agent. Our research results may contribute to expanding the therapeutic indications for the use of IMQ in anticancer therapy in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImiquimodToll-Like Receptor 7Neovascularization, PathologicAntineoplastic AgentsAminoquinolinesMelanoma, ExperimentalAnimalsMiceMice, Inbred C57BLHumansFemaleCell Line, TumorMembrane Glycoproteins

Stichwörter der Autor:innen

Antiangiogenic therapyBlood vessels normalizationDrug repurposingHypoxiaImiquimodTLR7 agonist

Substanzen

ImiquimodToll-Like Receptor 7Antineoplastic AgentsTlr7 protein, mouseAminoquinolinesMembrane Glycoproteins

Autor:innen und Institutionen

  • Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland. Magdalena.Jarosz-Biej@gliwice.nio.gov.pl.
  • Center for Translational Research and Molecular Biology of Cancer, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Poland.

Förderung

  • National Science Centre, Poland

Zitieren

APA

Magdalena, J. B., Justyna, C., Joanna, C., Ryszard, S., Alina, D., Dorota, S. L., Ewelina, P., Sybilla, M., & Tomasz, C. (2025). Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03943-2

Vancouver

Magdalena JB, Justyna C, Joanna C, Ryszard S, Alina D, Dorota SL, et al. Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-03943-2

BibTeX
@article{Magdalena2025,
  author = {Magdalena, Jarosz-Biej and Justyna, Czapla and Joanna, Ciepła and Ryszard, Smolarczyk and Alina, Drzyzga and Dorota, Sprus-Lipka and Ewelina, Pilny and Sybilla, Matuszczak and Tomasz, Cichoń},
  title = {Normalization of tumor vasculature by imiquimod: proposal for a new anticancer therapeutic indication for a TLR7 agonist},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-03943-2}
}
Kostenlos starten →